Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Prior genetic confirmation of a known mitochondrial disease mutation~2. Neurological features of MELAS (can be based on medical history)~3. Elevated plasma lactate levels at Screening Visit (≥1.0 mmol/L)~4. Women of childbearing potential must have a negative pregnancy test prior to randomization and must agree to use protocol-specified contraception from the Screening Visit through 90 days after the final dose of study drug.~5. Male participants must be surgically sterile by vasectomy (conducted ≥60 days before the Screening Visit or confirmed via sperm analysis) or must agree to use protocol-specified contraception and agree to refrain from sperm donation from the Screening Visit through 90 days after the final dose of study drug.~6. Other inclusion criteria per protocol~Exclusion Criteria:~1. Positive pregnancy test at Screening or on Day 1~2. Hypotension defined as systolic blood pressure (BP) ≤90 mmHg or diastolic BP ≤60 mmHg at Screening or predose at Day 1~3. Hypertension defined as systolic BP \>160 mmHg or diastolic BP \>100 mmHg, at Screening or predose at Day 1~4. Uncontrolled diabetes~5. Severe gastrointestinal dysmotility as determined by the investigator that may impact compliance and/or oral drug administration, absorption and exposure.~6. Unable to fast for 3-4 hours after a meal~7. Unable or unwilling to adhere to the study schedule, lifestyle restrictions, assessment requirements or, in the clinical judgment of the investigator, is otherwise not suitable for study participation.~8. Current or past history of clinically significant cardiomyopathy and/or cardiac conduction abnormality~9. Used any nicotine-containing products (eg, cigarettes, e-cigarettes, vape pens, cigars) within 1 month of enrollment~10. Other exclusion criteria per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IW-6463 (Type: EXPERIMENTAL): Open-label IW-6463 15 mg once daily (QD), with possibility to dose reduce to 10 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).